One-year results of four phase 3 trials of faricimab showed safety and efficacy comparable to aflibercept in the treatment of wet age-related macular degeneration and diabetic macular edema, with potentially longer treatment intervals.
Across all four pivotal studies, about 50% of patients treated with faricimab (Genentech) were able to achieve a treatment interval of 16 weeks, and more than 70% could be treated every 12 weeks or longer.
According to the authors of the studies, both published in The Lancet, these results represent a major step forward, potentially heralding an (Read more...)